Oncology (Page 1)

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

Cancer statistics, 2011

Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

Photodynamic therapy of cancer: An update

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

Cancer statistics, 2000

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Tamoxifen for early breast cancer: an overview of the randomised trials

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

<i>EGFR</i>Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Nivolumab plus Ipilimumab in Advanced Melanoma

Screening and Prostate-Cancer Mortality in a Randomized European Study

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Malignant Gliomas in Adults

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Hepatocellular carcinoma

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Hepatocellular carcinoma

The Eighth Edition <scp>AJCC</scp> Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

Dissemination and growth of cancer cells in metastatic sites

Ki67 expression in breast cancer

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Papillomaviruses and cancer: from basic studies to clinical application

WHO-EORTC classification for cutaneous lymphomas

Trastuzumab-Induced Hepatotoxicity: A Case Report

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Hepatocellular Carcinoma

Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study

AJCC Cancer Staging Manual

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer

Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer

<i>K-ras</i>Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

Osimertinib in Untreated<i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective

High Performance of &lt;sup&gt;18&lt;/sup&gt;F-Fluorodeoxyglucose Positron Emission Tomography and Contrast-Enhanced CT in a Rapid Outpatient Diagnostic Program for Patients with Suspected Lung Cancer

Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma

Triple-Negative Breast Cancer

Hepatocellular Carcinoma

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Crizotinib versus Chemotherapy in Advanced<i>ALK</i>-Positive Lung Cancer

Use of proteomic patterns in serum to identify ovarian cancer

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Integrins in cancer: biological implications and therapeutic opportunities

Diagnosis of gastrointestinal stromal tumors: A consensus approach

Cancer immunotherapy comes of age

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

Increasing Incidence of Thyroid Cancer in the United States, 1973-2002

Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Genomic Classification and Prognosis in Acute Myeloid Leukemia

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

Unique microRNA molecular profiles in lung cancer diagnosis and prognosis

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Estimates of the cancer incidence and mortality in Europe in 2006

Histological Grading and Prognosis in Breast Cancer

Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability